News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

BioPharm Executive - Golden Handshakes
Pfizer (PFE) Marries Allergan (AGN) in $160 Billion Deal With Pfizer’s Read to Stay as CEO and Chairman 11/23/2015
Pfizer (PFE), Servier Snap Up Right to Cellectis (ALCLS)' Blood Cancer Therapy in $338 Million+ Deal 11/19/2015
Mylan (MYL) Spurned Again as Perrigo (PRGO) Rejects $26 Billion Takeover Bid 11/13/2015
Johnson & Johnson (JNJ) Unit, Hanmi Pharma Ink Diabetes and Obesity Pact Worth $915 Million 11/9/2015
In Attempt to Bolster Sagging Diabetes Revenue, Sanofi (SNY) Inks Deal with Hanmi Pharma Worth $4.2 Billion 11/6/2015
Vertex (VRTX) Coughs Up $105 Million Upfront to CRISPR for Gene Editing Pact 10/26/2015
AbbVie (ABBV) and Alphabet's Ambitious Plan to Battle Immortality 10/20/2015
SSF's Five Prime (FPRX) Wrangles Immuno-Oncology Deal Worth $1.74 Billion Out of Bristol-Myers Squibb (BMY) 10/16/2015
Eli Lilly (LLY), China-based Innovent Biologics Expand Cancer Drug Collaboration With $1 Billion PD-1 Pact 10/12/2015
Arvinas Inks $300 Million Deal With Genentech (RHHBY) Over Protein Degradation Technology 10/2/2015
Amgen (AMGN) Scoops Up Dezima Pharma for $300 Million in Cash 9/17/2015
Perrigo (PRGO) Rejects Unsolicited Mylan (MYL) Bid 9/17/2015
Celgene (CELG), Nurix Team Up on $150M Drug Development Deal 9/17/2015
Biogen (BIIB) Forges $544M Deal to Take on Celgene (CELG) With a Rival Autoimmune Drug 9/11/2015
AstraZeneca PLC (AZN) Inks $445 Million Psoriasis Drug Pact With Valeant (VRX) After Amgen (AMGN) Bows Out 9/2/2015
In Puzzling Move, Novartis AG (NVS) Offers $1 Billion for GlaxoSmithKline (GSK)’s Ofatumumab for Auto-Immune Diseases 8/25/2015
BioMarin (BMRN) Sells Phase III Breast Cancer Drug to Medivation (MDVN) for $570 Million 8/25/2015
Bay Area's Raptor (RPTP) Beefs Up Portfolio With $453 Million Deal for Quinsair 8/21/2015
Valeant (VRX) Acquires Female Sex Drive Drug Maker Sprout for $1 Billion 8/21/2015
Genmab A/S (GEN.CO), Novo Nordisk A/S (NVO) Strike $452 Million+ DuoBody Tech Pact 8/14/2015
Teva (TEVA) Snaps Up Allergan (AGN) Generics for $40.5 Billion, Ends Pursuit of Mylan (MYL) 7/27/2015
Depomed (DEPO) Gets Sweetened $33 Per Share Offer From Horizon Pharma (HZNP) 7/21/2015
New Restructuring Leads to the Birth of Sanofi (SNY) and Its Plan to Expand 7/20/2015
Celgene (CELG) Swallows Up SoCal's Receptos (RCPT) in $7.2 Billion Deal 7/17/2015
AGTC (AGTC) Catapults Premarket on $1 Billion+ Eye Disease Pact With Biogen (BIIB) 7/6/2015
Johnson & Johnson (JNJ), Roche (RHHBY) Allegedly Circle GlaxoSmithKline (GSK) as Takeover Speculation Intensifies 6/26/2015
Almac Discovery Wrangles R&D Deal Worth $363.5 Million+ From Genentech (RHHBY) 6/16/2015
Tiny Startup Unum Forges $645 Million Pact With Seattle Genetics (SGEN) 6/9/2015
Celgene (CELG) Shells Out $82.5 Million in Cash for Portfolio, Option to Buy Lycera 6/9/2015
Tiny Parion Sciences Wrangles Lung Pact Worth $1.2 Billion From Vertex (VRTX) 6/8/2015
Alexion (ALXN) Plunks Down $8.4 Billion for Synageva BioPharma (GEVA), As Dealmaking Roars 5/7/2015
$60 Million Juno Therapeutics (JUNO) Deal Pushes Fate Therapeutics (FATE) Up 80% in Premarket Trading 5/7/2015
Isis Pharma (ISIS) Inks $155 Million Bayer (BAY) Deal Just After Good News From Biogen (BIIB) Collaboration 5/5/2015
Celgene (CELG) Slaps Down $450 Million Upfront for AstraZeneca PLC (AZN)'s Prized Immunotherapy Blood Cancer Drug 4/24/2015
Innate Pharma (IPH.PA ) Strikes Cancer Pact Worth $1.275 Billion With Pharma Giant AstraZeneca PLC (AZN) 4/24/2015
BREAKING: Perrigo (PRGO) Rejects $30B Mylan (MYL) Bid, Says Deal "Substantially Undervalues" Irish Firm 4/21/2015
Tiny Curadev Wrangles a $555 Million Pact With Drug Giant Roche (RHHBY) 4/20/2015
uniQure (QURE) Soars After Bristol-Myers Squibb (BMY) Bets $1 Billion on Gene Therapy Platform 4/7/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
AstraZeneca PLC (AZN), Daiichi Sankyo in $825 Million Drug Tie-Up 3/19/2015
Eli Lilly (LLY), Hanmi Pharma Forge $690 Million Autoimmune Pact 3/19/2015
AbbVie (ABBV) Overpaid in Pharmacyclics (PCYC) Deal, For Only 50% Rights to Imbruvica: Analyst 3/6/2015
Bristol-Myers Squibb (BMY) Bets $975 Million on Bavarian Nordic (BAVA.CO)'s Prostate Cancer Vaccine 3/5/2015
Spending Spree Continues as Valeant (VRX) Officially Snags Salix (SLXP) for $14.5 Billion 2/23/2015
Pfenex (PFNX), Hospira Pursue Lucentis Biosimilar in $342 Million Pact 2/11/2015
AstraZeneca PLC (AZN) Who? Pfizer (PFE) Snatches Up Hospira for $17 Billion Cash 2/6/2015
AstraZeneca PLC (AZN) Slams Down $600 Million for Actavis (ACT) Lung Unit 2/5/2015
Mylan (MYL), Theravance (THRX) Partner Up for $265 Million COPD Pact 2/2/2015
The New Billion Dollar Tekmira (TKMR) Includes Promising Hep B Drug 1/20/2015
Merck & Co. (MRK) Jumps Into RNA Frenzy With $100 Million Bet on Moderna Therapeutics, Inc. 1/14/2015
Tiny Vedanta Biosciences Forges $241 Million+ Pact With Johnson & Johnson (JNJ) 1/14/2015
Roche (RHHBY) Pays $1.03 Billion for Majority Stake in Foundation Medicine, Inc. (FMI) 1/12/2015
Shire (SHPGY) Officially Snaps Up NPS Pharmaceuticals, Inc. (NPSP) in $5.2 Billion Deal 1/12/2015
Opko Health, Inc. (OPK) Rockets After Striking Deal Worth $570 Million With Pfizer (PFE) 12/17/2014
Oncothyreon Inc. (ONTY) Strikes $300 Million Cancer Pact With Array BioPharma, Inc. (ARRY) 12/15/2014
Drug Giant Merck & Co. (MRK) Buys Cubist Pharmaceuticals, Inc. (CBST) For $9.5 Billion 12/11/2014
Spark Therapeutics Strikes $280 Million Hemophilia B Pact With Pfizer (PFE) 12/9/2014
GeNeuro, Servier Ink $455M MS Drug Pact 12/2/2014
Actavis (ACT) Agrees To Buy Allergan (AGN) For $66 Billion 11/18/2014
Pfizer (PFE), Merck KGaA (MKGAF.PK) Strike A $2.9B Deal To Develop Cancer Tumor Treatment 11/18/2014
Astellas Pharma Inc. (ALPMY), Proteostasis Therapeutics, Inc. Forge $1.2 Billion Genetic Disease Drug Pact 11/5/2014
Bristol-Myers Squibb (BMY) Strikes Deal Worth $444 Million With Galecto Biotech 11/4/2014
Five Prime Therapeutics, Inc. (FPRX) Snags An Expanded Deal Worth $196.3 Million With GlaxoSmithKline (GSK) 10/24/2014
SSF's Sutro Biopharma Forges $1 Billion+ And Option To Buy Pact With Celgene (CELG) 10/23/2014
Genentech (RHHBY), NewLink Genetics Strike $1 Billion+ Cancer Deal 10/21/2014
AbbVie (ABBV) Officially Abandons Shire 10/21/2014
Oxford BioMedica PLC (OXB.L) Inks Transformational $90 Million Deal With Novartis AG (NVS) 10/10/2014
South San Francisco's Sutro Biopharma Forges $375 Million Antibody Drug Pact With Merck KGaA (MKGAF.PK) 9/17/2014
Eli Lilly (LLY) Bets $500 Million On AstraZeneca PLC (AZN)’s Alzheimer's Drug 9/17/2014
More Than 35% Of Allergan Inc. (AGN) Investors Demand Special Meeting; Support For Valeant (VRX) Merger Grows 9/12/2014
Seattle Genetics, Inc. (SGEN), Genmab A/S (GEN.CO) Partner In $211 Million Antibody-Drug Pact 9/10/2014
AbbVie (ABBV) Hands Over $275 Million Upfront For Infinity Pharmaceuticals Inc. (INFI)’s Blood Cancer Drug; Deal Could Be Worth $805 Million 9/5/2014
Roche (RHHBY) Pays $8.3 Billion For Bay Area's InterMune (ITMN), Pledges To Keep Employees 8/26/2014
Pfizer (PFE) Eyes Possible Actavis (ACT) Bid Whilst Weighing Next Steps Over AstraZeneca PLC (AZN) 8/22/2014
Sanofi (France) (SAN.PA) To Pay MannKind Corporation (MNKD) Up To $925 Million For Inhaled Insulin 8/12/2014
Novartis AG (NVS), GlaxoSmithKline (GSK) Reshape Pharma With Game-Changing $14.5 Billion Deal 8/12/2014
Sanofi (France) (SAN.PA), Immune Design Corporation (IMDZ) Strike Food Allergy Deal Worth $168 Million+ 8/7/2014
Mylan Inc. (MYL)'s Overseas Move Will Lower Tax Rate 7/23/2014
AbbVie (ABBV) Finally Clinches Shire For $54 Billion 7/21/2014
Novartis AG (NVS), Google Inc. Strike Smart Contact Lenses Pact 7/15/2014
Genentech (RHHBY) To Pay Up To $1.7 Billion For San Diego Biotech Firm Seragon Pharmaceuticals 7/7/2014
Massachusett's bluebird bio (BLUE) Snaps Up Pregenen For Up To $139.9 Million 7/2/2014
Tapping University of California, San Francisco (UCSF) Invention, Roche (RHHBY) To Partner With San Diego Startup Inception Sciences, Versant Ventures To Form New Multiple Sclerosis Company 6/24/2014
Major Drugmakers Like AstraZeneca PLC (AZN), GlaxoSmithKline (GSK). And Johnson & Johnson (JNJ) Link Up With Academia In Huge $27 Million UK Dementia Project 6/20/2014
AstraZeneca PLC (AZN) Beefs Up Pipeline With $232 Million Synairgen plc Asthma Deal 6/12/2014
Merck & Co., Inc. (MRK) Snags Cambridge's Idenix Pharmaceuticals, Inc. (IDIX) For $3.85 Billion 6/11/2014
Adaptimmune Ltd., GlaxoSmithKline (GSK) Strike $350 Million Cancer Immunotherapy Pact 6/2/2014
Neurotez, Inc., GCA Therapeutics Strike $102.5 Million+ Alzheimer's Pact 5/21/2014
AstraZeneca PLC (AZN) Rejects Pfizer Inc. (PFE)'s Final Offer 5/20/2014
Ophthotech Corporation (OPHT) May Pocket $1 Billion From Eye Drug Deal With Novartis AG (NVS), Ophthotech Stock Up +24.48% At Market Close (May 20, 2014) 5/20/2014
Valeant Pharmaceuticals International (VRX) Will Sweeten $46 Billion Allergan Inc. (AGN) Bid 5/14/2014
Lundbeck Inc. (LUN.CO) Swallows Up Chelsea Therapeutics, Inc. (CHTP) In Deal Worth $658 Million 5/9/2014
Pfizer Inc. (PFE) Still Wants AstraZeneca PLC (AZN) After $98.7 Billion Bid Rejected 4/29/2014
Celgene Corporation (CELG) Antes Up $710 Million Upfront For Phase 3-Ready Crohn's Disease Drug 4/24/2014
Allergan Inc. (AGN) Curls Up Into Poison-Pill Position In Wake Of Valeant Pharmaceuticals International (VRX), Ackman Acquisition Bid 4/23/2014
FORMA Therapeutics, Inc. Picks Up Another $225 Million, And A Potential Buyout From Celgene (CELG) 4/2/2014
Baxter International, Inc. (BAX) To Split Into Two Companies, Spins Off $6 Billion Biotech Biz 3/28/2014
MedImmune (AZN), MD Anderson Cancer Center Agree To Launch Moon Shot At Cancer 3/20/2014
Five Prime Therapeutics, Inc. (FPRX), Bristol-Myers Squibb Company (BMY) Strike $350 Million Immuno-Oncology Pact 3/18/2014
Charles River Laboratories (Massachusetts) Shells Out $179 Million Cash To Buy Galapagos NV (GLPG.BR)'s CRO Services Division 3/13/2014
Top Biopharmas Such As Abbott Laboratories (ABT) And GlaxoSmithKline (GSK) Still Betting On "Messed Up" Indian Drugs Market 3/12/2014
Novartis AG (NVS) Chairman Rules Out Merger With Roche (RHHBY) 3/3/2014
Actavis (ACT) Bags Rival, Forest Laboratories, Inc. (FRX), For $25 Billion; Forest Stock Rockets +27.52% At Market Close (February 18, 2014) 2/19/2014
CoStim Pharmaceutical Buyout Bolsters Novartis AG (NVS)'s Cancer Portfolio 2/18/2014
Mallinckrodt Pharmaceuticals (MNK) Adds Pain Drug With $1.3 Billion Cash Cadence Pharmaceuticals, Inc. Buyout 2/11/2014
Eli Lilly and Company (LLY), Pfizer Inc. (PFE) And Eight Other Rivals Join The National Institutes of Health (NIH) In $230 Million Deal To Search For New Drugs 2/5/2014
Ablynx (ABLYF), Merck & Co., Inc. (MRK) Forge Cancer Pact Worth $2.3 Billion 2/3/2014
Nantbioscience Scores $75 Million Cancer Deal With Celgene Corporation (CELG) 1/16/2014
Regeneron (REGN), Bayer HealthCare (BAY) Forge Pact Worth $65 Million+ To Co-develop Wet AMD Drug 1/14/2014
Jazz Pharmaceuticals plc (JAZZ) Forges Pact Worth $397 Million For Aerial BioPharma's Sleepiness Drug 1/13/2014
Santaris Pharma A/S, Roche (RHHBY) Strike $148 Million+ Alliance To Design And Develop RNA-Targeted Drugs 1/10/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) May Pay Sangamo BioSciences, Inc. (SGMO) As Much As $320 Million For Blood Drugs; SGMA Soars +38.32% At Market Close (January 9, 2014) 1/9/2014
Roche (RHHBY) Inks Deal Worth Up To $600 Million For Prothena Corporation plc's Parkinson's Drug 12/13/2013
Biogen Idec, Inc. (Massachusetts) (BIIB), Proteostasis Therapeutics, Inc. Hammer Out $200 Million+ Pre-Clinical Alzheimer's Pact 12/9/2013
AstraZeneca PLC (AZN) Said To Be Eyeing Forest Laboratories, Inc. (FRX) Takeover Bid 12/4/2013
Roche (RHHBY), Molecular Partners AG Ink $1 Billion+ Cancer Pact 12/4/2013
Celgene Corporation (CELG) Smacks Down $177 Million Upfront For OncoMed Pharmaceuticals, Inc. (OMED)'s Stem Cell Drugs, Deal Is Potentially Worth $3.3 Billion; OMED Stock Up 97.86% at Market Close (December 3, 2013) 12/4/2013
immatics biotechnologies GmbH, Roche (RHHBY) Ink Cancer Pact Worth Up To $1 Billion 11/13/2013
Shire To Pay $4.2 Billion For Rare Disease Firm ViroPharma Incorporated (VPHM) 11/11/2013
ImmunoGen, Inc. (IMGN) Is On A Roll, Inks Fifth New License Agreement Of 2013 11/11/2013
Salix Pharmaceuticals, Ltd. (SLXP) Bags Santarus Inc. (SNTS) for $2.6 Billion to Beef Up Gastro Drug Line-Up 11/8/2013
Roche (RHHBY) to Pay Polyphor Up to $548 Million for Superbug Antibiotic 11/4/2013
Startup NextCODE Health, Launches Operations With $15 Million in Venture Financing 10/23/2013
Amgen (AMGN) Acquires Filgrastim Franchise Rights From Roche (RHHBY) in 100 Markets 10/23/2013
PDL BioPharma, Inc. (PDLI) Snatches Up Depomed, Inc. (DEPO)'s Diabetes Portfolio for $240.5 Million 10/22/2013
AmpliPhi Biosciences (TGEN) Signs Exclusive License With University of Leicester, UK to Develop Bacteriophage Therapies 10/17/2013
AstraZeneca PLC (AZN)'s MedImmune (AZN) Takes Over Spirogen Ltd. for Up to $400 Million to Bolster Oncolology Portfolio 10/15/2013
Ablynx (ABLYF) Scores $840 Million Inflammatory Drug Pact With AbbVie (ABBV); Ablynx Stock Rises 24.73% at Market Close (September 23, 2013) 9/23/2013
Clovis Oncology (CLVS) Looking to Sell Itself 9/18/2013
Roche (RHHBY), Inovio Pharmaceuticals (INO) Strike Vaccines Pact Worth $422.5 Million 9/11/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Makes $100 Million Upfront Payment in R&D Neurological Disorders Pact With Isis Pharmaceuticals, Inc. (ISIS) 9/9/2013
Japan's Otsuka Pharmaceutical Co., Ltd. Shells Out $886 Million for U.S. Cancer Firm Astex Pharmaceuticals (ASTX) 9/5/2013
Amgen (AMGN) Finally Reaches Deal to Buy Onyx Pharmaceuticals, Inc. (ONXX) for $10.4 Billion, AMGN Stock Rockets +7.72% on Monday @ Market Close (August 26, 2013) 8/26/2013
Adimab LLC. Adds Celgene Corporation (CELG) to Its Growing List of Big-Name Drugmaking Partners 8/20/2013
Shire plc Hires Adviser on Takeover Threat 8/20/2013
Array BioPharma, Inc. (ARRY) Says Amgen (AMGN) Ends Agreement, to Cut 20 Percent of Jobs 8/9/2013
Jazz Pharmaceuticals plc (JAZZ) and Alkermes plc (ALKS) are Seen as Next Targets Amid Irish Deal Frenzy: Real M&A 8/6/2013
Transition Therapeutics Inc. (TTH.TO) Buys Rights to Eli Lilly and Company (LLY)'s Arthritis Drug; Transition May be Eligible for $130 Million+ 7/24/2013
Pfizer Inc. (PFE) Not Moving Forward With Onyx Pharmaceuticals, Inc. (ONXX) Bid: Sources 7/19/2013
Quest Diagnostics Inc. (DGX) Sells Ibrutinib Royalty Rights to Royalty Pharma for $485 Million in Cash 7/18/2013
Spectrum Pharmaceuticals, Inc. (SPPI) Snaps Up Talon Therapeutics, Inc. (TLON.OB) in $206.3 Million Deal 7/17/2013
Array BioPharma, Inc. (ARRY), Loxo Oncology Strike $434 Million+ Cancer Pact 7/11/2013
AstraZeneca PLC (AZN) and NGM Biopharmaceuticals, Inc. Form Diabetes/Obesity Partnership 6/17/2013
Johnson & Johnson (JNJ) to Buy Aragon Pharmaceuticals, Inc. for Up to $1 Billion 6/17/2013
Johnson & Johnson (JNJ) Sells Final Stake in Elan Corporation PLC (ELN) for $332 Million 6/14/2013
Cytokinetics, Inc. (CYTK), Amgen (AMGN) Expand $75 Million Development Deal Into Japan 6/12/2013
AstraZeneca PLC (AZN) in Deal for Pearl Therapeutics Worth Up to $1.15 Billion 6/11/2013
Actavis (ACT) Nabs Warner Chilcott, PLC (WCRX) for $8.5 Billion 5/20/2013
AbbVie (ABBV), Galapagos NV (GLPG.BR) Ink $50 Million Crohn's Disease Pact 5/17/2013
AstraZeneca PLC (AZN), Cubist Pharmaceuticals, Inc. (CBST), Astellas Pharma Inc. (YPH.BE) Said to Make Bids for Optimer Pharmaceuticals, Inc. (OPTR) 5/15/2013
Elan Corporation PLC (ELN) Bets $1 Billion on Theravance, Inc. (THRX) Drugs; Move to Spurn Its Hostile Suitor? 5/13/2013
Concert Pharmaceuticals, Inc. and Celgene Corporation (CELG) Tie the Knot in a $300 Million Tech Deal 5/6/2013
Roche (RHHBY), Ascletis, Inc. to Collaborate on Hepatitis C Drugs for China 4/15/2013
GlaxoSmithKline (GSK) Targets "Electroceuticals" for Potential New Therapies 4/11/2013
GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical Engineering and Sciences to Develop New Medicines for Emerging Markets 4/9/2013
Resverlogix Corporation (RVX.TO) to Spin-Out RVX Therapeutics Inc. (RVX) 4/8/2013
Roche (RHHBY) and Isis Pharmaceuticals, Inc. (ISIS) Form $392 Million Alliance for Huntington's Disease 4/8/2013
AstraZeneca PLC (AZN) Shells Out $240 Million Upfront for Moderna Therapeutics mRNA Drugs 3/22/2013
bluebird bio Forms Cancer Drug Partnership With Celgene Corporation (CELG) 3/21/2013
Receptos Licenses AbbVie (ABBV) Antibody for Co-Development 3/14/2013
Astellas Pharma Inc. (YPH.BE) and Ambit Biosciences to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors 3/13/2013
Presage Biosciences Snags $13 Million From Celgene Corporation (CELG) to Pick Winning Cancer Drug Combos 3/5/2013
Roche (RHHBY) and Chiasma Inc. to Ally on Drug Development for Up to $600 Million 2/20/2013
Merck & Co., Inc. (MRK) and Samsung Corporation to Develop Biosimilar Drugs Together 2/20/2013
RQx Pharmaceuticals, Inc. Inks $111 Million Genentech (RHHBY) Deal 2/12/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) to Buy Elan Corporation PLC (ELN)'s Tysabri Rights for $3.25 Billion 2/7/2013
The Medicines Company (MDCO) Buys Cholesterol Drug Rights From Alnylam Pharmaceuticals (ALNY) for Up to $205 Million 2/5/2013
Allergan Inc. (AGN) to Buy MAP Pharmaceuticals, Inc. (MAPP) for $958 Million 1/23/2013
Life Technologies (LIFE) Gains on Buyout Speculation 1/21/2013
Shire plc Rises on AstraZeneca PLC (AZN) Bid Talk: Traders 1/17/2013
Amgen (AMGN), BIND Biosciences, Inc. Ink $180 Million Tumor Treatment Deal 1/8/2013
MacroGenics, Inc.'s DART Platform Grabs Potential $1 Billion Gilead Sciences, Inc. (GILD) Deal 1/8/2013
Gilead Sciences, Inc. (GILD) Bags Blood Disorder Drug With $510 Million YM BioSciences (YM.TO) Buy 12/13/2012
Amgen (AMGN) Bags Gene-Hunting Firm deCODE genetics, Inc. (DCGN) for $415 Million Cash 12/11/2012
Teva Pharmaceutical Industries Limited (TEVA) Enters $376 Million Deal for Xenon Pharmaceuticals Inc. Pain Drug 12/11/2012
Biogen Idec, Inc. (Massachusetts) (BIIB), Isis Pharmaceuticals, Inc. (ISIS) in Drug Development Pact for Up to $630 Million 12/10/2012
Sanofi (France) (SAN.PA) Deal Could Net Selecta Biosciences, Inc. $900 Million 11/29/2012
Johnson & Johnson (JNJ), Eli Lilly and Company (LLY), Merck & Co., Inc. (MRK) Team Up to Form Clinical Trial Site Database 11/15/2012
Forest Laboratories, Inc. (FRX) and Adamas Pharmaceuticals Form Alliance for Up to $160 Million 11/14/2012
Foundation Medicine and AstraZeneca PLC (AZN) Announce Genomic Profiling Collaboration 11/12/2012
Takeda Pharmaceutical Co. Ltd. (TKPYY) Shells Out $140 Million for Envoy Therapeutics 11/6/2012
Amgen (AMGN) Closes Deal With Financial Firm to Open New Biotech Company Atara Biotherapeutics 10/29/2012
Pfizer Inc. (PFE) Will Buy NextWave Pharmaceuticals for Up to $680 Million 10/23/2012
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/16/2012
Theravance, Inc. (THRX), Merck & Co., Inc. (MRK) Ink $153 Million Cardiovascular Pact 10/16/2012
AstraZeneca PLC (AZN) Boosts Pipeline With $272 Million Ardelyx Inc. Drug Deal 10/9/2012
Evotec AG (EVTG.F) and Bayer AG (BAY.F) Enter Into $765 Million Multi-Target Alliance to Fight Endometriosis 10/1/2012
MacroGenics, Inc. Could Earn More Than $1 Billion Through New Servier Alliance 9/20/2012
Baxter International, Inc. (BAX) and Onconova Therapeutics Inc. Announce European Licensing Agreement for Up to $515 Million 9/19/2012
Complete Genomics, Inc. to be Bought by Chinese Firm for $117.6 Million 9/17/2012
AstraZeneca PLC (AZN)'s MedImmune (AZN) Forms Chinese Joint Venture for Biologic Drug 9/11/2012
Genmab A/S (GEN.CO) Inks $1.1 Billion Deal With Johnson & Johnson (JNJ) 8/31/2012
Allergan Inc. (AGN), Molecular Partners AG Ink $1.5 Billion Exclusive Pact 8/21/2012
AstraZeneca PLC (AZN) Buys Into Regulus Therapeutics, Inc.' MicroRNA Therapeutics for $28 Million 8/15/2012
Elan Corporation PLC (ELN) Fuels Buyout Plans With $130 Million R&D Spinout, Unit Will Have Around 80 Staffers 8/14/2012
S*Bio of Singapore Sells Cancer Drug Rights to MEI Pharma (MEIP) (Formerly known as Marshall Edwards, Inc.) (MSHL) for $75 Million 8/10/2012
GlaxoSmithKline (GSK) Completes $3.6 Billion Takeover of Human Genome Sciences, Inc. (HGSI) 8/6/2012
Life Technologies (LIFE) Buys Navigenics for Genetic Diagnostics 7/17/2012
GlaxoSmithKline (GSK) Clinches Deal to Buy Human Genome Sciences, Inc. (HGSI) for $2.8 Billion 7/16/2012
Verastem, Inc. (VSTM) Buys Pfizer Inc. (PFE) Cancer Drug Candidate in Deal Worth $126.5 Million 7/12/2012